CDH17 and neoplasm: We observed that the inhibitory activity of BsADCs on tumor cell proliferation was dose-dependent, and this activity was significantly higher than that of the monospecific ADCs targeting CDH17 and GUCY2C individually (IC50, 4.97 μg/mL vs 27.72 μg/mL and 11.59 μg/mL in SW1463, 2.249 μg/mL vs 39.15 μg/mL and 10.02 μg/mL in LS1034) (Fig. 3C).